Figure 3.

The AMG510 sensitivity of 3D NCl-H23 spheroids under normoxia conditions. (a) The bright field images of NCl-H23 spheroids treated with AMG510 under normoxia (21% O₂); the drug doses include 0.001 μM, 0.005 μM, 0.01 μM, 0.05 μM, 0.1 μM, 1 μM, and 5 μM. (b) The cell viability and invasiveness analysis of NCl-H23 spheroids. (I) The cell viability of HCl-H23 spheroids treated with AMG510 within 10 days. (II) The cell viability of NCl-H23 spheroids treated with AMG510 on day 7; the data was normalized to control which was treated with 1% DMSO. (III) The diameters of NCl-H23 spheroids treated with AMG510 within 10 days. (IV) The diameters of HCl-H23 spheroids treated with AMG510 on the day 7 ratio to day 1. (V) The roughness of NCl-H23 spheroids treated with AMG510 within 10 days. (VI) The excess perimeter index (EPI) of NCl-H23 spheroids treated with AMG510 within 10 days. (VII) The tumor growth inhibition (TGI) of HCl-H23 spheroids treated with AMG510 on day 7. ***: p < 0.001, ns: not significant.